A5038737152- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Diverticular Disease and Complications
- Health Systems, Economic Evaluations, Quality of Life
- Helicobacter pylori-related gastroenterology studies
- Autoimmune and Inflammatory Disorders
- Biosimilars and Bioanalytical Methods
- Gastric Cancer Management and Outcomes
- Pediatric Hepatobiliary Diseases and Treatments
- Immunodeficiency and Autoimmune Disorders
- Gallbladder and Bile Duct Disorders
- Pancreatitis Pathology and Treatment
- Celiac Disease Research and Management
- Adolescent and Pediatric Healthcare
- Advanced Chemical Sensor Technologies
- Gut microbiota and health
- Anorectal Disease Treatments and Outcomes
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Chronic Disease Management Strategies
- Colorectal Cancer Treatments and Studies
- Asthma and respiratory diseases
- Diagnosis and treatment of tuberculosis
- Mycobacterium research and diagnosis
- Gastrointestinal Tumor Research and Treatment
Amphia Ziekenhuis
2016-2025
Breda University of Applied Sciences
2020
Maastricht University
2009-2017
University Medical Center
2014-2016
GTx (United States)
2016
University Hospital and Clinics
2014
Máxima Medisch Centrum
2006
Radboud University Nijmegen
2006
Ustekinumab is approved for the treatment of Crohn's disease [CD]. Systematically registered prospective real-world data are scarce. We therefore aimed to study effectiveness, safety and usage ustekinumab CD in everyday practice.We prospectively enrolled patients initiating regular care between December 2016 January 2019. Clinical (Harvey Bradshaw Index [HBI]), biochemical (C-reactive protein [CRP] faecal calprotectin [FCP]), extra-intestinal manifestations and, peri-anal fistula activity,...
Both vedolizumab and ustekinumab can be considered for the treatment of Crohn's disease (CD) when anti-TNF fails. However, head-to-head trials are currently not available or planned.To compare in Crohn´s patients a prospective registry specifically developed comparative studies with correction confounders.Crohn´s patients, who failed started standard care as second-line biological, were identified observational Dutch Initiative on Crohn Colitis Registry. Corticosteroid-free clinical...
Summary Background Tofacitinib is a Janus kinase inhibitor approved for the treatment of ulcerative colitis (UC). Aim To evaluate effectiveness, safety and use tofacitinib in daily practice. Methods UC patients initiating were prospectively enrolled 15 hospitals Netherlands. Corticosteroid‐free clinical remission (short activity index [SCCAI] ≤2), biochemical (faecal calprotectin level ≤250 µg/g), combined corticosteroid‐free remission, predictors outcomes, dose effect on lipids determined...
Microbiota composition and its metabolic capacity are very important for host health. Evidence suggests that gut microbiome is involved in the metabolites production by host-microbiome interaction. These can be absorbed blood excreted exhaled air. Although, profiles of microbiota were associated with gastrointestinal diseases, a direct link between them has not yet been investigated. The aim study was to investigate relation volatiles breath active quiescent Crohn's disease (CD) via...
The COVID-19 risk and disease course in inflammatory bowel [IBD] patients remains uncertain. Therefore, we aimed to assess the clinical presentation, course, outcomes of IBD patients. Second, determined incidences compared this with general population. We conducted a multicentre, nationwide cohort study Netherlands identified COVID-19. First, assessed outcomes. between our Dutch established an 34 763 was diagnosed 100/34 [0.29%]; 20/100 these [20%] had severe defined as admission intensive...
Objective The aim of this study was to describe the long-term health outcomes children born mothers with inflammatory bowel disease (IBD) and assess impact maternal IBD medication use on these outcomes. Design We performed a multicentre retrospective in Netherlands. Women who gave birth between 1999 2018 were enrolled from 20 participating hospitals. Information regarding characteristics, use, lifestyle, pregnancy retrieved medical charts. After consent both parents, until 5 years also...
Microbial shifts have been associated with disease activity in Crohn's [CD], but findings on specific taxa are inconsistent. This may be due to differences applied methods and cross-sectional study designs. We prospectively examined the faecal microbiota adult CD patients changing or stable course over time.Faeces were collected at two time-points from 15 healthy control individuals [HCs], 35 who remission maintained [RRs], 22 during also subsequent exacerbation [RAs]. The microbial...
Clinicians face difficulty in when and what order to position biologics Janus kinase inhibitors patients with anti-tumor necrosis factor-alpha (TNF) refractory ulcerative colitis (UC). We aimed compare the effectiveness safety of vedolizumab tofacitinib anti-TNF-exposed UC our prospective nationwide Initiative on Crohn Colitis Registry.Patients who failed anti-TNF treatment initiated or were identified Registry Netherlands. selected both clinical as well biochemical endoscopic disease...
Disappearance of macroscopic mucosal inflammation predicts long-term outcome in Crohn's disease (CD). It can be assessed by ileocolonoscopy, which is, however, an invasive and expensive procedure. Disease activity indices do not correlate well with endoscopic noninvasive markers have a low sensitivity subgroups patients. Volatile organic compounds (VOCs) breath are increasing interest as markers. The aim this study was to investigate whether VOCs accurately differentiate between active CD...
In youth with inflammatory bowel disease (IBD), health-related quality of life (HRQOL) has been shown to be affected by individual factors and specific psychological factors. The innovative aim this study is examine the combined impact (illness perceptions, cognitive coping, anxiety, depression) on HRQOL, over above associations demographic HRQOL in IBD.
Youths with inflammatory bowel disease (IBD) are at risk for developing anxiety and depressive symptoms a reported 20%-50% prevalence rate.This prospective study aimed to: (1) describe the severity of in large Dutch cohort young IBD patients, (2) identify demographic clinical factors depression.IBD patients (n = 374; 10-25 years) were screened anxiety, depression quality life using validated age-specific questionnaires. Patients elevated scores and/or received diagnostic interview assessing...
Summary Background Few data are available on the effects of age and comorbidity treatment outcomes vedolizumab ustekinumab in inflammatory bowel disease (IBD). Aims To evaluate association between with safety effectiveness IBD. Methods IBD patients initiating or regular care were enrolled prospectively. Comorbidity prevalence was assessed using Charlson Index (CCI). Association CCI, both continuously assessed, (any infection, hospitalisation, adverse events) during treatment, (clinical...
Ustekinumab is a monoclonal antibody that selectively targets p40, shared subunit of the cytokines interleukin [IL]-12 and IL-23. It registered for treatment inflammatory bowel diseases. We assessed 2-year effectiveness safety ustekinumab in real world, prospective cohort patients with Crohn's disease [CD].Patients who started were prospectively enrolled nationwide Initiative on Crohn Colitis [ICC] Registry. At weeks 0, 12, 24, 52 104, clinical remission Harvey Bradshaw Index≤ 4 points],...
Abstract Background Hospitals in the southwest of Netherlands collaborate to improve inflammatory bowel disease (IBD) care. As part this initiative, a standardised care pathway (CP) for treatment IBD with biologics and small new molecules has been developed. The CP addresses initiation, switching, discontinuation therapy, as well diagnostic testing follow-up. implemented six eight hospitals patient outcomes, standardise reduce healthcare costs. This natural experiment provides an opportunity...
Abstract Background Eight hospitals in the southwest of Netherlands collaborate to improve care for patients with inflammatory bowel disease (IBD). This collaboration aims deliver high quality and uniform across region. To achieve this, a pathway (CP) was developed implemented management IBD biologicals or small new molecules. The CP is decision-support tool that provides guidelines medication prescribing, procedures, treatment adjustments, recommendations follow-up. aim this study evaluate...
Abstract Background Filgotinib is a preferential JAK1-inhibitor approved for the treatment of ulcerative colitis (UC). The ICC registry was developed to evaluate effectiveness and safety advanced therapies in inflammatory bowel disease (IBD). Here, we report one-year follow-up results filgotinib patients with UC. Methods Fourteen hospitals prospectively enrolled UC initiating Dutch registry. Treatment persistence assessed by Kaplan-Meier survival analysis. Clinical remission (i.e. Simple...
Abstract Background In the randomized controlled LADI trial, a subset of patients with Crohn’s disease (CD) maintained clinical remission following extension adalimumab dose interval (1). The aim this study was to assess long-term outcomes for trial participants who extended 3 or 4 weeks compared conventional dosing. Methods At baseline, we enrolled CD in biochemical and corticosteroid-free (CFCR) on 40 mg/2 weeks. intervention group started 3-week increased at week 24, if remission....
Abstract Background The impact of overweight and obesity on treatment outcomes in inflammatory bowel disease (IBD) remains unclear, as current literature is inconclusive often restricted to selected patient populations. We examined the effect Body Mass Index (BMI) response patients with IBD starting various treatments. Methods Patients ≥ 16 years old IBD, a documented baseline BMI, thiopurines allopurinol, intravenous (iv) vedolizumab, subcutaneous (sc) ustekinumab, ozanimod, filgotinib, or...
Abstract Background In the southwest of Netherlands, there is a close collaboration between hospitals to improve care for inflammatory bowel disease (IBD). This aims deliver high quality and uniform across region. To achieve this, pathway (CP) was developed implemented treating IBD with biologics small new molecules. The CP consists subsets that address initiation switching therapy, frequency type follow-up. study assess adherence determine barriers facilitators development implementation....
Abstract Background Ulcerative proctitis (UP) is associated with disabling symptoms including diarrhea, hematochezia and bowel urgency1. Adequate therapy crucial for symptom control may reduce the risk of proximal disease extension. Although prior studies have explored factors progression, they are limited by small sample sizes conflicting results2,3. Therefore, aim this study was (1) to assess incidence (2) identify progression in newly diagnosed UP patients. Methods All patients...
ABSTRACT Background The impact of prophylactic medication following ileocecal resection (ICR) for Crohn's disease (CD) merits further elucidation. Prophylactic is recommended in patients with Crohn’s (CD), particularly at increased risk recurrence, but the on long‐term outcomes needs to be elucidated. Aim To evaluate effect postoperative prognosis. Methods A retrospective cohort study was performed CD who underwent primary ICR between 2000‐2020 Netherlands. Patients were divided into two...
Currently there is no guideline for the treatment of patients with Crohn's disease and high perianal fistulas. Most receive anti-TNF medication, but long-term results this expensive medication have been described, nor has its efficiency compared to surgical strategies. With study, we hope provide consensus daily clinical practice reduction in costs. This a multicentre, randomized controlled trial. Patients who are over 18 years age, newly diagnosed or recurrent active fistulas, one internal...